Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,347 active trials7 approved drugs177 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,063 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03262636 | Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)(TumorGlow(TM)) | completed | Phase 1 | 363 | University of PennsylvaniaOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04216329 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH |
| 1 |
| Jan 23, 2026 |
| clinicaltrials |
| NCT05556473 | F-Tryptophan PET/CT in Human Cancers | recruiting | Phase 1 | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07353229 | 68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma | suspended | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | recruiting | Phase 1 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor(GABRIEL) | not yet recruiting | Phase 1 | 15 | Sarah RumlerOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT05211336 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | terminated | Phase 1 | 1 | Baptist Health South FloridaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07306299 | A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04165941 | Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma(DRI) | active not recruiting | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT02473380 | Fluorescence Spectroscopy Guided Surgery(GLIOSPECT) | completed | Phase 1 | 11 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07193628 | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma | recruiting | Phase 1 | 14 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06132945 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | active not recruiting | Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | active not recruiting | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 23, 2026source: clinicaltrials